ENLV - Enlivex Therapeutics Ltd. Total Debt to Capital

This price chart illustrating changes in the total debt-to-equity ratio of Enlivex Therapeutics (ENLV) is fixed at 0.00. Enlivex Therapeutics develops cutting-edge immunotherapy methods against sepsis, where low demand elasticity guarantees a stable cash flow. The development of Allocetra allows for the modulation of macrophage function to mitigate cytokine storms, a process monitored by FDA and EU regulators within the framework of global clinical trials.

This indicator measures financial leverage by dividing total credit obligations by the amount of equity to assess the business's degree of dependence on borrowed funds. By analyzing the debt-to-equity ratio, an investor determines the ability of Enlivex Therapeutics (ENLV) to finance costly developments in macrophage immunotherapy without falling behind larger competitors in the capital-intensive race for intellectual property.